Forest Laboratories, Inc. (FRX) Coughs Up $25 Million for Nabriva Therapeutics's Phase II Antibacterial, Right to Take Over Company
6/1/2012 6:42:35 AM
More...
|
Nabriva Therapeutics Chooses TransPerfect Trial Interactive to Oversee Its Licensing Process
9/27/2011 10:42:28 AM
More...
|
Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781
9/19/2011 10:33:08 AM
More...
|
Nabriva Therapeutics Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI
4/18/2011 10:48:33 AM
More...
|
Nabriva Therapeutics Completes Recruitment for Phase II of Pleuromutilin Antibiotic BC-3781
1/10/2011 10:51:34 AM
More...
|
Nabriva Therapeutics' Pleuromutilin Antibiotic BC-3781 Shows Therapeutic Potential for Skin and Lung Infections with both Oral and IV Dosing in Non-Clinical and Clinical Phase I Studies
9/10/2010 11:35:17 AM
More...
|
Nabriva Therapeutics Initiates Phase II Of Pleuromutilin Antibiotic BC-3781
6/2/2010 11:32:05 AM
More...
|
Nabriva Therapeutics Raises $22 Million
10/28/2009 7:25:29 AM
More...
|
Nabriva Therapeutics Initiates Clinical Phase I Trial of Pleuromutilin Antibiotic BC-3781
7/23/2009 1:45:38 PM
More...
|
Nabriva Therapeutics Appoints New Supervisory Board Member
5/7/2009 12:19:51 PM
More...
|
|